Some of the names on the move ahead of the open.» Read More
Baxter International Inc. rose$. 71 or. 9 percent, to $75.96. Bristol-Myers Squibb Co. fell$. 13 or. 2 percent, to $49.92. Hospira fell$. 12 or. 2 percent, to $54.79.
Baxter International Inc. rose$. 12 or. 2 percent, to $75.25. Bristol-Myers Squibb Co. fell$. 26 or. 5 percent, to $50.04. Hospira rose$. 99 or 1.8 percent, to $54.91.
Baxter International Inc. rose$. 11 or. 1 percent, to $75.24. Bristol-Myers Squibb Co. fell$. 18 or. 4 percent, to $50.12. Hospira rose$. 70 or 1.3 percent, to $54.62.
Baxter International Inc. fell$. 35 or. 5 percent, to $74.78. Bristol-Myers Squibb Co. fell$. 16 or. 3 percent, to $50.14. Hospira rose$. 45 or. 8 percent, to $54.37.
Baxter International Inc. fell$. 08 or. 1 percent, to $75.13. Bristol-Myers Squibb Co. rose$. 31 or. 6 percent, to $50.30. Hospira fell $1.56 or 2.8 percent, to $53.92.
Baxter International Inc. rose$. 01 or percent, to $75.22. Bristol-Myers Squibb Co. fell$. 15 or. 3 percent, to $49.84. Hospira fell $1.18 or 2.1 percent, to $54.30.
Baxter International Inc. rose$. 80 or 1.1 percent, to $75.21. Bristol-Myers Squibb Co. rose$. 31 or. 6 percent, to $49.99. Hospira rose$. 46 or. 8 percent, to $55.48.
Diversified U.S. manufacturer 3 M Co and medical equipment makers CareFusion Corp and C.R. Bard Inc are among the companies exploring a potential deal for ConvaTec, the people said. CareFusion, with a market capitalization of $9 billion, and C.R. Bard, with $11.2 billion, would both be able to achieve an inversion if they use their own stock to pay for ConvaTec.
Baxter International Inc. rose$. 81 or 1.1 percent, to $75.22. Bristol-Myers Squibb Co. rose$. 13 or. 3 percent, to $49.81. Hospira rose$. 76 or 1.4 percent, to $55.78.
Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.
LONDON, July 31- AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. AstraZeneca said it would present further data looking at MEDI4736 in lung cancer, as well as early results for head and neck cancer, in September at the annual meeting of the European Society for Medical Oncology.
Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.
NEW YORK, July 24- Major global stock markets edged higher while the euro rose from an eight-month low against the U.S. dollar on Thursday following upbeat euro zone data and stronger-than-expected U.S. earnings.
U.S. stock index futures rose on Thursday, ahead of one of the heaviest days for U.S. and European second-quarter earnings.
Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.
You always hear Cramer shouting about Bristol – Maaah-yerss. Why is that?
July 1- Bristol-Myers Squibb Co said it was voluntarily recalling six lots of the injectable version of its blood thinner, Coumadin, in the United States, after particulate matter was found in some unreleased samples.